Osaka, Japan

Hideki Horiuchi

This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignee: Mitsubishi Tanabe Pharma Corporation. Active years: 2013-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideki Horiuchi. Retrieved from https://idiyas.com/inventor/hideki-horiuchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 75.0

 

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Hideki Horiuchi

Introduction

Hideki Horiuchi is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds. With a total of 4 patents to his name, Horiuchi's work has the potential to impact various therapeutic areas.

Latest Patents

Horiuchi's latest patents include a bicyclic heterocyclic compound that demonstrates a superior inhibitory action on KAT-II. This invention encompasses a production method, its use, and a pharmaceutical composition containing the compound. Additionally, he has developed a bicyclic or tricyclic heterocyclic compound represented by a specific formula, which includes an optionally substituted aromatic group.

Career Highlights

Horiuchi is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to innovate in the pharmaceutical sector. His work focuses on creating compounds that can lead to effective treatments for various medical conditions.

Collaborations

Horiuchi has collaborated with notable colleagues such as Masahiro Okuyama and Kenji Fukunaga, contributing to the advancement of their shared research goals.

Conclusion

Hideki Horiuchi's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a significant inventor. His work continues to pave the way for new therapeutic options in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…